Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

The Lilly Biotechnology Center in San Diego, California, on March 1, 2023.

Mike Blake | Reuters

Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw lower realized prices.

The figures were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors. Eli Lilly had slashed its 2024 revenue guidance, as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations.

The company’s earnings topped Wall Street estimates, but sales fell just short.

Here’s what Eli Lilly reported for the period compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

Earnings per share: $5.32 adjusted vs. $4.95 expected
Revenue: $13.53 billion vs. $13.57 billion expected

This story is developing. Please check back for updates.

Source

Health

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill

October 21, 2025

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely watched pill from […]

Health

Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat

October 21, 2025

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images Cattle ranchers in Texas and around the country […]

Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

October 20, 2025

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery. Claude for Life Sciences is […]